Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
The first dipeptidyl-peptidase-IV (DPP-4) inhibitor for the treatment of type 2 diabetes became available in 2006. Since then, the number of DPP-4 inhibitors has increased and DPP-4 inhibitors have developed into an important drug class. DPP-4 inhibitors act by increasing endogenous GLP-1 and GIP co...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3540954/ |